Search
Search Results
-
A variability in response of osteoclasts to zoledronic acid is mediated by smoking-associated modification in the DNA methylome
BackgroundClinical trials have shown zoledronic acid as a potent bisphosphonate in preventing bone loss, but with varying potency between patients....
-
-
Expression of angiogenic markers in jawbones and femur in a rat model treated with zoledronic acid
ObjectivesThis study aimed to investigate the gene expression of angiogenic marker in surgically treated jawbones and femur on a rat model...
-
The TOPAZ study: a home-based trial of zoledronic acid to prevent fractures in neurodegenerative parkinsonism
The Trial of Parkinson’s And Zoledronic acid (TOPAZ, https://clinicaltrials.gov/ct2/show/NCT03924414 ) is a unique collaboration between experts in...
-
Evaluation of disseminated tumor cells and circulating tumor cells in patients with breast cancer receiving adjuvant zoledronic acid
We evaluated disseminated tumor cells (DTCs) and circulating tumor cells (CTCs) in patients with stage I-III breast cancer with >4 MM/mL DTC at...
-
Zoledronic acid-loaded lipidic nanoparticles enhance apoptosis and attenuate invasiveness by inhibiting epithelial to mesenchymal transition (EMT) in HepG2 cancer cells
The aim of this study was to evaluate the potential of zoledronic acid (ZOL)-loaded lipidic nanoparticles (ZOL-NLCs) in enhancing the efficiency of...
-
Effect of Liposome-Encapsulated Zoledronic Acid on Microenvironment of Hepatocellular Carcinoma May Depend on the Ratio Between M1 and M2 Polarized Macrophages
We studied the effect of zoledronic acid encapsulated into liposomes (L-ZOL) on tumorassociated macrophages in the stroma of hepatocellular carcinoma...
-
Effects of once-yearly zoledronic acid on bone density and incident vertebral fractures in nonmetastatic castration-sensitive prostate cancer patients with osteoporosis
BackgroundAndrogen deprivation therapy (ADT) is the effective treating prostate cancer but is often accompanied by cancer treatment-induced bone loss...
-
Various pathways of zoledronic acid against osteoclasts and bone cancer metastasis: a brief review
Zoledronic acid (ZA) is one of the most important and effective class of anti-resorptive drug available among bisphosphonate (BP), which could...
-
Comparative Treatment Persistence with Bone-Targeting Agents Among Asian Patients with Bone Metastases from Solid Tumors: A Multinational Retrospective Cohort Study
BackgroundThe efficacy of bone-targeting agents has been confirmed, but the generalizability of results to Asia is in question.
Objective ...
-
Cancer and Hypercalcemia
Alterations of calcium homeostasis leading to hypercalcemia can occur at three different levels: the bone (increased osteoclast activity), kidney...
-
Zoledronic acid inhibits TSC2-null cell tumor growth via RhoA/YAP signaling pathway in mouse models of lymphangioleiomyomatosis
BackgroundThis study is to investigate the effects of zoledronic acid (ZA) on TSC2-null cell proliferation and on the tumor progression and...
-
Denosumab-induced hypocalcemia in patients with solid tumors and renal dysfunction: a multicenter, retrospective, observational study
BackgroundBone metastases are frequently observed in advanced cancer, and bone modifying agents are used to prevent or treat skeletal-related events....
-
Real-world use of bone modifying agents in metastatic, castration-resistant prostate cancer
BackgroundBone modifying agents (BMAs) prevent skeletal related events among patients with metastatic, castration-resistant prostate cancer (mCRPC)...
-
The effect of zoledronic acid on attenuation of bone loss at the hip and knee following acute traumatic spinal cord injury: a randomized-controlled study
Study designRandomized double blind, placebo-controlled trial.
ObjectivesTo examine the effect of early intravenous zoledronic acid (ZA) on bone...
-
Author Correction: Synergistic suppression of human breast cancer cells by combination of plumbagin and zoledronic acid in vitro
The authors regretted to find the mis-representative images in Fig. 3a, c and Fig. 4a, c when re-read our previously published article Synergistic...
-
Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression
BackgroundOsteoporosis is a common phenomenon in HIV patients on tenofovir treatment, but its underlying mechanisms remain to be explored.
...
-
The relevance of acid sphingomyelinase as a potential target for therapeutic intervention in hepatic disorders: current scenario and anticipated trends
Acid sphingomyelinase (ASMase) serves as one of the most remarkable enzymes in sphingolipid biology. ASMase facilitates the hydrolysis of...
-
The prognostic potential of alkaline phosphatase and lactic acid dehydrogenase in bmCRPC patients without significant PSA response under enzalutamide
BackgroundIn patients with bone metastatic castration-resistant prostate cancer (bmCRPC) on systemic treatment, it is difficult to differentiate...
-
Zoledronic acid inhibits the growth of cancer stem cell derived from cervical cancer cell by attenuating their stemness phenotype and inducing apoptosis and cell cycle arrest through the Erk1/2 and Akt pathways
BackgroundZoledronic acid is the most potent osteoclast inhibitor and is widely used for advanced cancer patients with bone metastasis, but its role...
